Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory S Merrick

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|August 9, 2011
Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapyNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|October 4, 2005
The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapyAngela Niehaus, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trialGregory S Merrick, Kent E Wallner, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|July 8, 2010
Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapyAl V Taira, Gregory S Merrick, Wayne M Butler, et al.
BJU International|August 2, 2006
Brachytherapy in men aged < or = 54 years with clinically localized prostate cancerGregory S Merrick, Kent E Wallner, Wayne M Butler, et al.
Urology|December 20, 2005
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancerMark A Moyad, Gregory S Merrick, Wayne M Butler, et al.
Urologic Oncology|December 1, 2009
Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostateNathan Bittner, Gregory S Merrick, Renee Stewart, et al.
Brachytherapy|January 23, 2017
The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancerNathan H J Bittner, Peter F Orio, Gregory S Merrick, et al.
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Long-term rectal function after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|August 9, 2011
Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapyNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|October 4, 2005
The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapyAngela Niehaus, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trialGregory S Merrick, Kent E Wallner, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|July 8, 2010
Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapyAl V Taira, Gregory S Merrick, Wayne M Butler, et al.
BJU International|August 2, 2006
Brachytherapy in men aged < or = 54 years with clinically localized prostate cancerGregory S Merrick, Kent E Wallner, Wayne M Butler, et al.
Urology|December 20, 2005
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancerMark A Moyad, Gregory S Merrick, Wayne M Butler, et al.
Urologic Oncology|December 1, 2009
Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostateNathan Bittner, Gregory S Merrick, Renee Stewart, et al.
Brachytherapy|January 23, 2017
The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancerNathan H J Bittner, Peter F Orio, Gregory S Merrick, et al.
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Long-term rectal function after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Pageof 19